440
Views
19
CrossRef citations to date
0
Altmetric
Drug Profile

The safety and efficacy of vandetanib in the treatment of progressive medullary thyroid cancer

, , , , , , & show all
Pages 1109-1118 | Received 17 May 2016, Accepted 16 Sep 2016, Published online: 30 Sep 2016

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (3)

Silvia Martina Ferrari, Giusy Elia, Francesca Ragusa, Sabrina Rosaria Paparo, Valeria Mazzi, Mario Miccoli, Maria Rosaria Galdiero, Gilda Varricchi, Rudy Foddis, Giovanni Guglielmi, Claudio Spinelli, Concettina La Motta, Salvatore Benvenga, Alessandro Antonelli & Poupak Fallahi. (2021) Lenvatinib: an investigational agent for the treatment of differentiated thyroid cancer. Expert Opinion on Investigational Drugs 30:9, pages 913-921.
Read now
Poupak Fallahi, Silvia Martina Ferrari, Giusy Elia, Francesca Ragusa, Sabrina Rosaria Paparo, Ilaria Ruffilli, Armando Patrizio, Gabriele Materazzi & Alessandro Antonelli. (2019) Evaluating vandetanib in the treatment of medullary thyroid cancer: patient-reported outcomes. Cancer Management and Research 11, pages 7893-7907.
Read now
Silvia Martina Ferrari, Poupak Fallahi, Concettina La Motta, Giusy Elia, Francesca Ragusa, Ilaria Ruffilli, Armando Patrizio, Enke Baldini, Salvatore Ulisse & Alessandro Antonelli. (2019) Recent advances in precision medicine for the treatment of anaplastic thyroid cancer. Expert Review of Precision Medicine and Drug Development 4:1, pages 37-49.
Read now

Articles from other publishers (16)

Sneha Krishnamoorthy, Loganayaki Periyasamy, G. Jayapradha, Rajalakshmi Sabanayagam, Hemnath Elango, M. Vishwanathan & Sridhar Muthusami. 2023. Phospholipases in Physiology and Pathology. Phospholipases in Physiology and Pathology 141 158 .
Carla Colombo, Simone De Leo, Matteo Trevisan, Noemi Giancola, Anna Scaltrito & Laura Fugazzola. (2022) Daily Management of Patients on Multikinase Inhibitors’ Treatment. Frontiers in Oncology 12.
Crossref
Poupak Fallahi, Silvia Martina Ferrari, Giusy Elia, Francesca Ragusa, Armando Patrizio, Sabrina Rosaria Paparo, Gianni Marone, Maria Rosaria Galdiero, Giovanni Guglielmi, Rudy Foddis, Alfonso Cristaudo & Alessandro Antonelli. (2022) Primary cell cultures for the personalized therapy in aggressive thyroid cancer of follicular origin. Seminars in Cancer Biology 79, pages 203-216.
Crossref
Paulina Wdowiak, Joanna Matysiak, Piotr Kuszta, Katarzyna Czarnek, Ewa Niezabitowska & Tomasz Baj. (2021) Quinazoline Derivatives as Potential Therapeutic Agents in Urinary Bladder Cancer Therapy. Frontiers in Chemistry 9.
Crossref
Ming Hua Ge, Xu Hang Zhu, Yi Ming Shao, Chao Wang, Ping Huang, Yun Wang, Yu Jiang, Yasen Maimaitiyiming, En Chen, Chang Yang & Hua Naranmandura. (2021) Synthesis and characterization of CD133 targeted aptamer–drug conjugates for precision therapy of anaplastic thyroid cancer. Biomaterials Science 9:4, pages 1313-1324.
Crossref
Yasemin AYDOĞAN ÜNSAL, Özen ÖZ GÜL, Canan ERSOY, Soner CANDER, Oktay ÜNSAL & Erdinç ERTÜRK. (2020) Metastatik Tiroid Medüller Karsinom Olgularında Vandetanib Tedavisi: Tek Merkez DeneyimiVandetanib Treatment in Patients with Metastatic Thyroid Medullary Carcinoma: Single Center Experience. Uludağ Üniversitesi Tıp Fakültesi Dergisi 46:3, pages 263-269.
Crossref
Julie M. Janssen, Thomas P. C. Dorlo, Neeltje Steeghs, Jos H. Beijnen, Lidwien M. Hanff, Natasha K. A. van Eijkelenburg, Jasper van der Lugt, C. Michel Zwaan & Alwin D. R. Huitema. (2020) Pharmacokinetic Targets for Therapeutic Drug Monitoring of Small Molecule Kinase Inhibitors in Pediatric Oncology. Clinical Pharmacology & Therapeutics 108:3, pages 494-505.
Crossref
Te-Sheng Chang, Chung-Kuang Lu, Yung-Yu Hsieh, Kuo-Liang Wei, Wei-Ming Chen, Sui-Yi Tung, Cheng-Shyong Wu, Michael W. Y. Chan & Ming-Ko Chiang. (2020) 2,4-Diamino-Quinazoline, a Wnt Signaling Inhibitor, Suppresses Gastric Cancer Progression and Metastasis. International Journal of Molecular Sciences 21:16, pages 5901.
Crossref
Saeid Kargozar, Francesco Baino, Sepideh Hamzehlou, Michael R. Hamblin & Masoud Mozafari. (2020) Nanotechnology for angiogenesis: opportunities and challenges. Chemical Society Reviews 49:14, pages 5008-5057.
Crossref
Helena Montanuy, Águeda Martínez-Barriocanal, José Antonio Casado, Llorenç Rovirosa, Maria José Ramírez, Rocío Nieto, Carlos Carrascoso-Rubio, Pau Riera, Alan González, Enrique Lerma, Adriana Lasa, Jordi Carreras-Puigvert, Thomas Helleday, Juan A. Bueren, Diego Arango, Jordi Minguillón & Jordi Surrallés. (2020) Gefitinib and Afatinib Show Potential Efficacy for Fanconi Anemia–Related Head and Neck Cancer. Clinical Cancer Research 26:12, pages 3044-3057.
Crossref
Xiaobo Li, Yong Li, Weijin Lu, Minfeng Chen, Wencai Ye & Dongmei Zhang. (2019) The Tumor Vessel Targeting Strategy: A Double-Edged Sword in Tumor Metastasis. Cells 8:12, pages 1602.
Crossref
Thomas D. Milner, Milind Ronghe, Mohamad G. Shaikh, Fiona B. MacGregor & Nicholas Reed. (2019) Vandetanib Tumor Shrinkage in Metastatic Medullary Thyroid Cancer Allowing Surgical Resection of the Primary Site: A Case Report. Journal of Pediatric Hematology/Oncology 41:5, pages e329-e332.
Crossref
Robert RoskoskiJr.Jr.. (2019) Properties of FDA-approved small molecule protein kinase inhibitors. Pharmacological Research 144, pages 19-50.
Crossref
Ira L. Kraft, Srivandana Akshintala, Yuelin Zhu, Haiyan Lei, Claudia Derse-Anthony, Eva Dombi, Seth M. Steinberg, Maya Lodish, Steven G. Waguespack, Oxana Kapustina, Elizabeth Fox, Frank M. Balis, Maria J. Merino, Paul S. Meltzer, John W. Glod, Jack F. Shern & Brigitte C. Widemann. (2018) Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib. Clinical Cancer Research 24:4, pages 753-765.
Crossref
Sadegh Rajabi & Mehdi Hedayati. (2017) Medullary Thyroid Cancer: Clinical Characteristics and New Insights into Therapeutic Strategies Targeting Tyrosine Kinases. Molecular Diagnosis & Therapy 21:6, pages 607-620.
Crossref
Chengyan Wang, Hongchun Liu, Zilan Song, Yinchun Ji, Li Xing, Xia Peng, Xisheng Wang, Jing Ai, Meiyu Geng & Ao Zhang. (2017) Synthesis and structure–activity relationship study of pyrazolo[3,4- d ]pyrimidines as tyrosine kinase RET inhibitors. Bioorganic & Medicinal Chemistry Letters 27:11, pages 2544-2548.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.